SI-B036 for Cancer

This trial tests a new treatment called SI-B036, a potential drug for people with advanced solid tumors. The main goal is to assess the safety and tolerability of this treatment for patients whose cancer has progressed despite other therapies. Participants should have a solid tumor that cannot be surgically removed and have already tried at least one standard treatment without success. The trial seeks individuals whose cancer impacts their daily life and who are looking for new options. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

Yes, you will need to stop certain medications before joining the trial. Specifically, you must not have had chemotherapy, biological therapy, immunotherapy, or targeted therapy within 4 weeks or 5 half-lives before the first dose, and you must not have taken immunosuppressive drugs within 2 weeks prior to the first dose.

A previous study showed that SI-B036 holds promise for treating solid tumors. However, detailed safety information from human trials remains unavailable. This trial is in its first phase, focusing primarily on assessing the drug's safety and tolerability. Researchers are still investigating possible side effects and how the body processes the drug. Early trials typically aim to determine the correct dose and identify any adverse reactions. Participants in this trial will contribute valuable information about the drug's safety.¹²³⁴⁵

Unlike other treatments for cancer that typically involve chemotherapy or targeted therapy, SI-B036 is unique because it is administered as an intravenous (IV) infusion every three weeks. Researchers are excited about SI-B036 as it may offer a new mechanism of action that targets cancer cells differently than traditional treatments. This could potentially lead to more effective outcomes and reduced side effects, providing a new hope for patients with cancer.

Research has shown that SI-B036, which participants in this trial will receive, is a new treatment designed to fight solid tumors in cancer patients. This treatment targets specific parts of cancer cells, potentially stopping their growth. Although limited information exists from human studies, early results suggest that similar treatments have slowed tumor growth in some patients. This offers hope that SI-B036 might work similarly. More studies are needed to confirm these early signs and fully understand its effectiveness.⁶⁷⁸⁹¹⁰